
I-Mab (IMAB) Stock Forecast & Price Target
I-Mab (IMAB) Analyst Ratings
Bulls say
I-MAB's stock outlook is supported by its advanced drug pipeline, notably the promising development of Givastomig, which demonstrates a favorable safety profile and higher binding affinity, indicating enhanced efficacy and potential for expanded market opportunities. The anticipated Hong Kong IPO is expected to diversify the shareholder base and help align I-MAB's valuation with that of its Asia-listed peers, potentially enhancing investor interest and market perception. Moreover, the appointment of a new CFO with substantial capital markets experience bolsters I-MAB's financial strategy and enhances investor communication ahead of significant clinical milestones projected for 2026.
Bears say
I-MAB's stock experienced a decline of approximately 12% following recent announcements, indicating potential investor concerns and profit-taking activities. The company's decision to implement a hub-and-spoke model, alongside existing capacity constraints, raises questions about its operational efficiency and future growth potential. These fundamental challenges within I-MAB's strategic focus contribute to a negative outlook on its financial prospects.
This aggregate rating is based on analysts' research of I-Mab and is not a guaranteed prediction by Public.com or investment advice.
I-Mab (IMAB) Analyst Forecast & Price Prediction
Start investing in I-Mab (IMAB)
Order type
Buy in
Order amount
Est. shares
0 shares